文献速递先天性心脏病外科

心外管道全腔静脉肺动脉连接转换的长期疗效

Long-term therapeutic effect of Fontan conversion with an extracardiac conduit.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

本研究回顾1991至2014年36例接受心外管道全腔静脉肺动脉连接(TCPC)转换的患者,中位转换年龄24.1岁,随访8.2±4.8年。10年生存率79.2%,无蛋白丢失性肠病生存率67.8%,维持窦性心律生存率48.5%。转换后肺动脉压力、肺血管阻力和心脏指数显著改善并维持,运动耐量未下降。

要点

  • TCPC转换后10年生存率79.2%,无蛋白丢失性肠病生存率67.8%。
  • 转换后肺动脉压力、肺血管阻力和心脏指数显著改善并长期维持。
  • 转换可预防经典Fontan患者运动耐量的自然下降。

核心结论

  • 心外管道TCPC转换具有抗心律失常和Fontan通路招募效应,可防止经典Fontan患者运动耐量的自然下降。

研究设计与样本

  • 回顾性队列研究,纳入1991至2014年36例接受心外管道TCPC转换的患者,中位年龄24.1岁(IQR 18.9-29.2),中位转换间隔17.8年(IQR 15.4-20.9)。

主要发现

  • 10年实际生存率79.2%,无蛋白丢失性肠病生存率67.8%,维持窦性心律生存率48.5%。
  • 肺动脉压力从11.0±3.1降至9.5±3.6 mmHg(P=0.003),肺血管阻力从2.1±0.7降至1.3±0.5 WU/m2(P<0.0001),心脏指数从2.0±0.3升至2.9±0.6 l/min/m2(P<0.0001),改善维持至随访结束。
  • 峰值摄氧量从术前49.7±11.5%预测值至1年52.5±12.0%、5年56.2±9.6%、10年51.2±9.4%(P=0.19),无显著变化。
  • 术后新发蛋白丢失性肠病2例,永久起搏器植入12例(33%),其余患者无持续性房性心动过速。

临床怎么用

  • 对于经典Fontan术后出现运动耐量下降或心律失常的患者,可考虑心外管道TCPC转换以改善血流动力学并维持运动能力。

局限性

  • 样本量较小(36例),为单中心回顾性研究,随访时间较长但部分检查完成率随随访时间下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to identify the long-term therapeutic effect of total cavopulmonary connection (TCPC) conversion with an extracardiac conduit. METHODS: Between 1991 and 2014, 36 patients underwent TCPC conversion with an extracardiac conduit. Half of these patients were diagnosed with tricuspid atresia or its variant. The left ventricle was dominant in 26 patients (72.2%). Median age at conversion and interval from initial Fontan operation to conversion were 24.1 years (interquartile range 18.9-29.2) and 17.8 years (15.4-20.9), respectively. Surgical cryoablation was concomitantly performed in 32 patients (88.9%). Cardiac catheter examination was performed preoperatively (36 patients, 100%) and at 1 year (31 patients, 86%), 5 years (25 patients, 69%) and 10 years (13 patients, 36%) after TCPC conversion. Symptom-limited treadmill exercise with expired gas analysis was performed preoperatively (32 patients, 88.9%) and at 1 year (27 patients, 75.0%), 5 years (20 patients, 55.6%) and 10 years (12 patients, 33.3%) after conversion. RESULTS: All patients received follow-up; the mean follow-up period was 8.2 ± 4.8 years. Actuarial survival rate, protein-losing enteropathy-free survival rate and rate of survival with sinus rhythm maintenance at 10 years were 79.2%, 67.8% and 48.5%, respectively. The survival curve declined steeply when the duration of Fontan circulation exceeded 25 years. New cases of protein-losing enteropathy developed postoperatively in 2 patients. Permanent pacemakers were implanted in 12 patients (33%), but atrial tachyarrhythmia was not sustained in any of the remaining patients. Pulmonary arterial pressure (11.0 ± 3.1 to 9.5 ± 3.6 mmHg, P = 0.003), pulmonary vascular resistance (2.1 ± 0.7 to 1.3 ± 0.5 WU/m2, P < 0.0001) and cardiac index (2.0 ± 0.3 to 2.9 ± 0.6 l/min/m2, P < 0.0001) significantly improved from preoperative evaluation to 1 year after the conversion, and these improvements were maintained during the entire follow-up period. Peak oxygen uptake remained unchanged from the preoperative evaluation (49.7 ± 11.5% predicted) to 1 year (52.5 ± 12.0%), 5 years (56.2 ± 9.6%) and 10 years (51.2 ± 9.4%) after conversion (P = 0.19). CONCLUSIONS: Owing to its anti-arrhythmic effect and Fontan pathway recruitment effect, TCPC conversion with an extracardiac conduit prevented the natural decline of exercise tolerance that is seen in classic Fontan patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hoashi T, Shimada M, Imai K, et al. Long-term therapeutic effect of Fontan conversion with an extracardiac conduit. Eur J Cardiothorac Surg. 2020. PMID: 31883324. doi:10.1093/ejcts/ezz355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。